Key result
Micra VVI pacing complication risk does not differ between patients with and without AF.
Why the study?
Patient selection criteria and outcomes for leadless single-chamber VVI pacing in patients with and without atrial fibrillation were not well described.
Does the presence of an atrial fibrillation indication affect the risk of cardiac failure, pacemaker syndrome, or syncope in patients receiving leadless single-chamber VVI pacing?
Cohort (n=720)
Does the presence of an atrial fibrillation indication affect the risk of cardiac failure, pacemaker syndrome, or syncope in patients receiving leadless single-chamber VVI pacing?
Leadless single-chamber VVI pacing carries a low risk of pacemaker syndrome, heart failure, or syncope, regardless of whether the primary indication is associated with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports low complication risk with Micra VVI across AF indications; observational data leave open need for randomized confirmation.
AIMS: Patient selection is a key component of securing optimal patient outcomes with leadless pacing. We sought to describe and compare patient characteristics and outcomes of Micra patients with and without a primary pacing indication associated with atrial fibrillation (AF) in the Micra IDE trial. METHODS AND RESULTS: The primary outcome (risk of cardiac failure, pacemaker syndrome, or syncope related to the Micra system or procedure) was compared between successfully implanted patients from the Micra IDE trial with a primary pacing indication associated with AF or history of AF (AF group) and those without (non-AF group). Among 720 patients successfully implanted with Micra, 228 (31.7%) were in the non-AF group. Reasons for selecting VVI pacing in non-AF patients included an expectation for infrequent pacing (66.2%) and advanced age (27.2%). More patients in the non-AF group had a condition that precluded the use of a transvenous pacemaker (9.6% vs. 4.7%, P = 0.013). Atrial fibrillation patients programmed to VVI received significantly more ventricular pacing compared to non-AF patients (median 67.8% vs. 12.6%; P < 0.001). The overall occurrence of the composite outcome at 24 months was 1.8% with no difference between the AF and non-AF groups (hazard ratio 1.36, 95% confidence interval 0.45-4.2; P = 0.59). CONCLUSION: Nearly one-third of patients selected to receive Micra VVI therapy were for indications not associated with AF. Non-AF VVI patients required less frequent pacing compared to patients with AF. Risks associated with VVI therapy were low and did not differ in those with and without AF.
No takes yet. Share an insight, caveat, or question.
Piccini et al. (2019) conducted a cohort in Patients requiring single-chamber VVI pacing (n=720). Primary pacing indication associated with atrial fibrillation (AF) vs. No primary pacing indication associated with AF (non-AF) was evaluated on Risk of cardiac failure, pacemaker syndrome, or syncope related to the Micra system or procedure (HR 1.36, 95% CI 0.45-4.2, p=0.59). In patients receiving Micra VVI pacing, the risk of pacing-related complications at 24 months did not differ between those with and without an AF indication.
Synapse has enriched 10 related papers. Consider them for comparative context: